五苓散加减防治结(直)肠癌FOLFIRI方案化疗相关性腹泻临床研究.pdfVIP

五苓散加减防治结（直）肠癌 FOLFIRI 方案化疗相关性腹泻的临床研究 黄学武 黄丹云 广州中医药大学第一附属医院肿瘤科，广东，广州 510405 【摘要】 目的 观察内服经典方剂五苓散对结（直）肠癌患者接受 FORFIRI 方案化疗发生化疗相关 性腹泻的预防和治疗作用。方法 采用前瞻性非随机对照研究方法，收集符合纳入标准的病例共 60 例，其中治疗组和对照组各 30 例。治疗组使用 FOLFORI 方案化疗，并于化疗的第一天起予五苓散加 减中药内服，对照组单用 FOLFORI方案化疗，不予中药内服。结果：内服中药五苓散加减对结（直） 肠癌 FORFIRI 方案治疗出现化疗相关性腹泻的病人有明显防治作用（P＜0.05），对结（直）肠癌 FORFIRI 方案化疗后患者 KPS 评分变化的短期作用优势不明显（P＞0.05）。结论：内服中药五苓散 加减可防治结（直）肠癌 FORFIRI方案所致化疗相关性腹泻的发生，并具有一定的安全性。 【关键词】 化疗相关性腹泻；五苓散；结（直）肠癌 The Clinical Study of Prevention and Treatment for Bower Cancer FORFIRI Chemotherapy-induced diarrhea with Prescriptions Xuewu Huang，DanYun Huang，The first affiliated hospital of Guangzhou TCM university Guangzhou 510405,China 【Abstract】ObjectiveThis clinical study that designed as a prospective clinical randomized controlled study, observing the prevention and treatment for Bower Cancer FORFIRI Chemotherapy-induced diarrhea with Prescriptions WULING.Methods The clinical study prospective clinical randomized controlled study, the 30 cases of the treatment group sourced from the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, the 30 cases of the control group sourced from the Armed Police Hospital of Guangdong Province. ALL case accept the chemotherapy of FORFIRI, the treatment group take prescriptions WULING from day one till the end, the control group receive no Chinese medicine. This trial, by observing the changes of clinical symptoms, KPS scoring position and security of Prescriptions WULING, provides objective meaningful clinical data for the prevention and treatment for CID with Prescriptions WULING.Results The Prescriptions WULING can obviously prevent and treat for Bower Cancer FORFIRI Chemotherapy-induced diarrhea(P＜0.05）. The improvement of symptoms is obviouser at the day 7 after chemotherapy than the day 14,though t